Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Legend Biotech Corp
LEGN | US
23.90
USD-0.09
-0.38%
LEGN | US
Loading StockChartView...
About Legend Biotech Corp
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
23.90
Open
24.08
High
24.32
Low
23.23
Legend Biotech Corporation a clinical-stage biopharmaceutical company through its subsidiaries engages in the discovery development manufacturing and commercialization of novel cell therapies for oncology and other indications in the United States China and internationally. Its lead product candidate LCAR- B38M is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers including Non-Hodgkins Lymphoma acute lymphoblastic leukemia gastric cancer esophageal cancer pancreatic cancer colorectal cancer hepatocellular carcinoma small cell lung cancer and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
View LessLEGN | US
Risk
84.2
Sharpe
-0.68
Luna's Score
57/100
Recommendation
Hold
Luna says (LEGN | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
Midcap (2B - 10B USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
108.3%1 month
84.2%3 months
62.6%6 months
58.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
357.14
Price to book
6.85
Debt to equity
0.29
Debt to assets
0.19
Ent. to EBITDA
-15.34
Ent. to rev.
15.32
PEG
-
Other Fundamentals
EBITDA
-362.43M
MarketCap
4.40B
MarketCap(USD)
4.40B
Div. yield
-
Op. margin
-22.50
Erngs. growth
-
Rev. growth
154.40
Ret. on equity
-22.21
Short ratio
12.36
Short perc.
12.46
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
9.07
Range1M
10.02
Range3M
10.48
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.61
Price X volume
31.55M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -15.34 | 0.53 | Cheaper |
| Ent. to Revenue | 15.32 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 6.85 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 62.63 | 72.80 | Par |
| Debt to Equity | 0.29 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 4.40B | 3.66B | Market Leader |
